论文部分内容阅读
目的观察尼莫地平治疗晚发型维生素K1缺乏颅内出血的临床疗效及预后分析。方法 2005-2010年收住我院的晚发型维生素K1缺乏颅内出血83例(出血部位在脑实质、硬脑膜下腔、蛛网膜下腔、脑室内),分为治疗组47例,对照组36例,治疗组在综合治疗的基础上,于入院后48h内鼻饲或口饲尼莫地平,1次/8h,1mg·kg-1·8h-1,10d为1疗程。对其临床资料进行分析。结果治疗组显效34例,总有效40例,总有效率85.11%,且治疗过程中未见任何不良反应;对照组显效15例,总有效21例,总有效率58.33%。结论尼莫地平治疗晚发型维生素K1缺乏颅内出血疗效明显,有利于减少并发症,降低后遗症率及死亡率。
Objective To observe the clinical efficacy and prognosis of nimodipine in treating late-onset vitamin K1-deficient intracranial hemorrhage. Methods From 2005 to 2010, 83 cases of late-onset vitamin K1 lacking intracranial hemorrhage (bleeding site in the parenchyma, subdural space, subarachnoid space and ventricle) were divided into treatment group (n = 47) and control group Cases, the treatment group on the basis of comprehensive treatment, nasal feeding or oral feeding within 48h after nimodipine, 1 / 8h, 1mg · kg-1 · 8h-1, 10d for a course of treatment. The clinical data analysis. Results In the treatment group, 34 cases were markedly effective, 40 cases were effective and the total effective rate was 85.11%. There were no adverse reactions in the treatment group. The control group showed markedly effective in 15 cases and the total effective rate was 21 cases. The total effective rate was 58.33%. Conclusion Nimodipine treatment of late-onset vitamin K1 lack of intracranial hemorrhage was significantly effective in reducing complications and reducing sequelae and mortality.